138 related articles for article (PubMed ID: 12044553)
1. Chromatographic removal combined with heat, acid and chaotropic inactivation of four model viruses.
Valdés R; Ibarra N; Ruibal I; Beldarraín A; Noa E; Herrera N; Alemán R; Padilla S; Garcia J; Pérez M; Morales R; Chong E; Reyes B; Quiñones Y; Agraz A; Herrera L
J Biotechnol; 2002 Jul; 96(3):251-8. PubMed ID: 12044553
[TBL] [Abstract][Full Text] [Related]
2. The removal of model viruses, poliovirus type 1 and canine parvovirus, during the purification of human albumin using ion-exchange chromatographic procedures.
Cameron R; Davies J; Adcock W; MacGregor A; Barford JP; Cossart Y; Harbour C
Biologicals; 1997 Dec; 25(4):391-401. PubMed ID: 9467035
[TBL] [Abstract][Full Text] [Related]
3. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
[TBL] [Abstract][Full Text] [Related]
5. Removal and inactivation of enveloped and non-enveloped viruses during the purification of a high-purity factor IX by metal chelate affinity chromatography.
Roberts PL; Walker CP; Feldman PA
Vox Sang; 1994; 67 Suppl 1():69-71. PubMed ID: 8091741
[TBL] [Abstract][Full Text] [Related]
6. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of viruses using novel protein A wash buffers.
Bolton GR; Selvitelli KR; Iliescu I; Cecchini DJ
Biotechnol Prog; 2015; 31(2):406-13. PubMed ID: 25482293
[TBL] [Abstract][Full Text] [Related]
8. Validation of model virus removal and inactivation capacity of an erythropoietin purification process.
Pérez M; Rodríguez E; Rodríguez M; Paez R; Ruibal I; Noa E; García O; Moya G; Martínez M; Marcelo J; Martínez A; Dubal M; Navea L; Valdés R
Biologicals; 2011 Nov; 39(6):430-7. PubMed ID: 21982851
[TBL] [Abstract][Full Text] [Related]
9. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
10. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
11. A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.
Poelsler G; Berting A; Kindermann J; Spruth M; Hämmerle T; Teschner W; Schwarz HP; Kreil TR
Vox Sang; 2008 Apr; 94(3):184-192. PubMed ID: 18167162
[TBL] [Abstract][Full Text] [Related]
12. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
13. Manufacturing process of anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance.
Morrica A; Nardini C; Falbo A; Bailey AC; Bucci E
Biologicals; 2003 Sep; 31(3):165-73. PubMed ID: 12935804
[TBL] [Abstract][Full Text] [Related]
14. The removal of viruses during the purification of equine antisera using filtration aids Hyflo Super-Cel and Fulmon Super A.
Cameron-Smith R; Miloradovic L; Cheyne I; Healy K
Biologicals; 2000 Sep; 28(3):169-74. PubMed ID: 10964443
[TBL] [Abstract][Full Text] [Related]
15. Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process.
Bos OJ; Sunyé DG; Nieuweboer CE; van Engelenburg FA; Schuitemaker H; Over J
Biologicals; 1998 Dec; 26(4):267-76. PubMed ID: 10403030
[TBL] [Abstract][Full Text] [Related]
16. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors.
Roberts PL
Biologicals; 2014 Jul; 42(4):184-90. PubMed ID: 24981392
[TBL] [Abstract][Full Text] [Related]
17. Removal of poliovirus type 1 from a protein mixture using an immunoaffinity chromatography column.
Cameron-Smith R; Harbour C
Biomed Chromatogr; 2001 Nov; 15(7):471-83. PubMed ID: 11746244
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of lipid enveloped viruses by octanoic Acid treatment of immunoglobulin solution.
Dichtelmüller H; Rudnick D; Kloft M
Biologicals; 2002 Jun; 30(2):135-42. PubMed ID: 12127315
[TBL] [Abstract][Full Text] [Related]
19. Biological Safety of a Highly Purified 10% Liquid Intravenous Immunoglobulin Preparation from Human Plasma.
Goussen C; Simoneau S; Bérend S; Jehan-Kimmel C; Bellon A; Ducloux C; You B; Paolantonacci P; Ollivier M; Burlot L; Chtourou S; Flan B
BioDrugs; 2017 Jun; 31(3):251-261. PubMed ID: 28508264
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the inactivation of canine and bovine parvovirus by freeze-drying and dry-heat treatment in two high purity factor VIII concentrates.
Roberts PL; Hart H
Biologicals; 2000 Sep; 28(3):185-8. PubMed ID: 10964445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]